<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="213981">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300391</url>
  </required_header>
  <id_info>
    <org_study_id>0505051</org_study_id>
    <secondary_id>1K23HL078760-01A1</secondary_id>
    <nct_id>NCT00300391</nct_id>
  </id_info>
  <brief_title>ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium</brief_title>
  <official_title>ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treating delirious intensive care unit patients
      with haloperidol improves mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intensive care unit delirium is a serious medical condition that is associated with
      increased morbidity and mortality. In this study, 304 delirious mechanically ventilated
      subjects will be randomized to haloperidol 5mg IV every 12 hours or placebo to determine if
      treatment with haloperidol improves short and long-term mortality.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment to meet aims.
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day all-cause mortality</measure>
    <time_frame>Daily</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 Days from enrollment in study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total delirium days</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>haloperidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once diagnosed as delirious, randomized to haloperidol 5 mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once diagnosed as delirious, received 5 mg saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol</intervention_name>
    <description>Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.</description>
    <arm_group_label>haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>control arem</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult (&gt;=18 years of age) mechanically ventilated patients admitted to the
             medical, surgical, trauma, or cardiothoracic ICUs of the UPMC main campus who are
             expected by the ICU clinical team to require &gt;24 hours of mechanical ventilation

        Exclusion Criteria:

          -  Baseline QTc &gt;480 milliseconds (ms); history of Parkinson's disease; pregnancy;
             history of schizophrenia or neurologic disease that would confound the delirium
             assessment; deafness or inability to understand English or Spanish; extubation prior
             to enrollment; previously enrolled in this study; patient, family, or attending
             physician refusal; death before enrollment; treatment with haloperidol within 2 days
             prior to ICU admission; and prisoners.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric B Milbrandt, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Milbrandt EB, Kersten A, Kong L, Weissfeld LA, Clermont G, Fink MP, Angus DC. Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med. 2005 Jan;33(1):226-9; discussion 263-5.</citation>
    <PMID>15644675</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 10, 2016</lastchanged_date>
  <firstreceived_date>March 6, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Barb Early</investigator_full_name>
    <investigator_title>MACRO Clinical Director</investigator_title>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Haloperidol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
